GETUG12_2 | R Documentation |
Kaplan-Meier digitized data from GETUG12, figure 2 (PMID 26028518). A reported sample size of 207 for a primary endpoint of RFS in prostate cancer.
GETUG12_2
A data frame of 413 observations and 3 variables:
time | event time (in years) | |
event | RFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (adt, adt_de) | |
Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015; 16: 787–94.
summary(GETUG12_2)
kmplot(GETUG12_2)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.